Three-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study.
3-year outcomes
CLASP
DMR
FMR
TEER
mitral repair
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
27
03
2023
received:
22
12
2022
accepted:
30
04
2023
medline:
4
7
2023
pubmed:
14
5
2023
entrez:
13
5
2023
Statut:
ppublish
Résumé
Mitral valve transcatheter edge-to-edge repair (M-TEER) is an effective option for treatment of mitral regurgitation (MR). We previously reported favorable 2-year outcomes for the PASCAL transcatheter valve repair system. We report 3-year outcomes from the multinational, prospective, single-arm CLASP study with analysis by functional MR (FMR) and degenerative MR (DMR). Patients with core-lab determined MR ≥ 3+ were deemed candidates for M-TEER by the local heart team. Major adverse events were assessed by an independent clinical events committee to 1 year and by sites thereafter. Echocardiographic outcomes were evaluated by the core laboratory to 3 years. The study enrolled 124 patients, 69% FMR; 31% DMR (60% NYHA class III-IVa, 100% MR ≥ 3+). The 3-year Kaplan-Meier estimate for survival was 75% (66% FMR; 92% DMR) and freedom from heart failure hospitalization (HFH) was 73% (64% FMR; 91% DMR), with 85% reduction in annualized HFH rate (81% FMR; 96% DMR) (p < 0.001). MR ≤ 2+ was achieved and maintained in 93% of patients (93% FMR; 94% DMR) and MR ≤ 1+ in 70% of patients (71% FMR; 67% DMR) (p < 0.001). The mean left ventricular end-diastolic volume (181 mL at baseline) decreased progressively by 28 mL [p < 0.001]. NYHA class I/II was achieved in 89% of patients (p < 0.001). The 3-year results from the CLASP study demonstrated favorable and durable outcomes with the PASCAL transcatheter valve repair system in patients with clinically significant MR. These results add to the growing body of evidence establishing the PASCAL system as a valuable therapy for patients with significant symptomatic MR.
Sections du résumé
BACKGROUND
Mitral valve transcatheter edge-to-edge repair (M-TEER) is an effective option for treatment of mitral regurgitation (MR). We previously reported favorable 2-year outcomes for the PASCAL transcatheter valve repair system.
OBJECTIVES
We report 3-year outcomes from the multinational, prospective, single-arm CLASP study with analysis by functional MR (FMR) and degenerative MR (DMR).
METHODS
Patients with core-lab determined MR ≥ 3+ were deemed candidates for M-TEER by the local heart team. Major adverse events were assessed by an independent clinical events committee to 1 year and by sites thereafter. Echocardiographic outcomes were evaluated by the core laboratory to 3 years.
RESULTS
The study enrolled 124 patients, 69% FMR; 31% DMR (60% NYHA class III-IVa, 100% MR ≥ 3+). The 3-year Kaplan-Meier estimate for survival was 75% (66% FMR; 92% DMR) and freedom from heart failure hospitalization (HFH) was 73% (64% FMR; 91% DMR), with 85% reduction in annualized HFH rate (81% FMR; 96% DMR) (p < 0.001). MR ≤ 2+ was achieved and maintained in 93% of patients (93% FMR; 94% DMR) and MR ≤ 1+ in 70% of patients (71% FMR; 67% DMR) (p < 0.001). The mean left ventricular end-diastolic volume (181 mL at baseline) decreased progressively by 28 mL [p < 0.001]. NYHA class I/II was achieved in 89% of patients (p < 0.001).
CONCLUSIONS
The 3-year results from the CLASP study demonstrated favorable and durable outcomes with the PASCAL transcatheter valve repair system in patients with clinically significant MR. These results add to the growing body of evidence establishing the PASCAL system as a valuable therapy for patients with significant symptomatic MR.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-154Subventions
Organisme : Edwards Lifesciences
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011.
Iung B, Delgado V, Rosenhek R, et al. Contemporary presentation and management of valvular heart disease: the EURObservational research programme valvular heart disease II survey. Circulation. 2019;140:1156-1169.
Dziadzko V, Clavel MA, Dziadzko M, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018;391:960-969.
Goliasch G, Bartko PE, Pavo N, et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J. 2018;39:39-46.
Dziadzko V, Dziadzko M, Medina-Inojosa JR, et al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome. Eur Heart J. 2019;40:2194-2202.
Levine RA, Hagége AA, Judge DP, et al. Mitral valve disease-morphology and mechanisms. Nat Rev Cardiol. 2015;12:689-710.
Del Forno B, De Bonis M, Agricola E, et al. Mitral valve regurgitation: a disease with a wide spectrum of therapeutic options. Nat Rev Cardiol. 2020;17:807-827.
Iung B, et al. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. Eur Heart J. 2003;24:1231-1243.
Szerlip M, Spargias KS, Makkar R, et al. 2-Year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. JACC. 2021;14:1538-1548.
Lim DS, Kar S, Spargias K, et al. Transcatheter valve repair for Patients With mitral regurgitation. JACC. 2019;12:1369-1378.
Webb JG, Hensey M, Szerlip M, et al. 1-Year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. JACC. 2020;13:2344-2357.
Stone GW, Adams DH, Abraham WT, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: Part 2: endpoint definitions. JACC. 2015;66:308-321.
Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation. J Am Soc Echocardiogr. 2017;30:303-371.
Biaggi P, Felix C, Gruner C, et al. Assessment of mitral valve area during percutaneous mitral valve repair using the MitraClip system: comparison of different echocardiographic methods. Circulation. 2013;6:1032-1040.
Altiok E, Hamada S, Brehmer K, et al. Analysis of procedural effects of percutaneous edge-to-edge mitral valve repair by 2D and 3D echocardiography. Circulation. 2012;5:748-755.
Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat Med. 2007;26:4505-4519.
Mack MJ, Lindenfeld J, Abraham WT, et al. 3-Year outcomes of transcatheter mitral valve repair in patients with heart failure. JACC. 2021;77:1029-1040.
Kar S, Feldman T, Qasim A, et al. Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients. Heart. 2019;105:1622-1628.
Feldman T. The EVEREST II REALISM continued access non-high risk study: mid- and long-term follow-up in surgical candidates. Eur Heart J. 2017;38:4176.
Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter Edge-to-Edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients. JACC Cardiovasc Interv. 2022;15:2523-36.
Buzzatti N, De Bonis M, Denti P, et al. What is a “good” result after transcatheter mitral repair? impact of 2+ residual mitral regurgitation. J Thorac Cardiovasc Surg. 2016;151:88-96.
Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States. JACC. 2017;70:2315-2327.
Geyer M, Keller K, Tamm AR, et al. Early symptomatic benefit indicates long-term prognosis after transcatheter mitral valve edge-to-edge repair in functional and degenerative etiology. Int J Cardiol. 2021;344:141-146.
Hahn RT, Hausleiter J. Transmitral gradients following transcatheter Edge-to-Edge repair: are mean gradients meaningful? JACC Cardiovasc Interv. 2022;15:946-949.